Moleculin Biotech Raises Capital via Inducement Warrant Agreements

An announcement from Moleculin Biotech ( (MBRX) ) is now available.

On February 19, 2026, Moleculin Biotech entered into inducement agreements with certain warrant holders, prompting the exercise of existing warrants to buy up to 2,122,652 shares at $3.90 each, which is expected to generate gross proceeds of about $8.3 million before fees. In exchange, Moleculin issued new Series H inducement warrants for up to 6,367,956 shares, featuring a five-year term, anti-dilution price-reset protections with a floor of $0.962, beneficial ownership caps of up to 9.99%, and a commitment by the company to register the resale of the underlying shares by spring 2026, moves that bolster liquidity but add potential future equity dilution for investors.

The Inducement Warrants may be exercised only after shareholder approval and can be exercised on a cashless basis if resale registration is unavailable, while in certain fundamental transactions holders are entitled to receive the Black Scholes value of the warrants as consideration. The transaction, for which Roth Capital Partners acted as financial advisor with a 7% fee on gross proceeds and legal cost reimbursement, underscores Moleculin’s continued reliance on structured equity-linked financings to support its operations, with the new unregistered warrants issued under a private offering exemption and structured to manage ownership concentration and market impact over time.

The most recent analyst rating on (MBRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue losses, ongoing cash burn, and prior negative equity) and bearish technicals (below key moving averages with negative MACD). Positive corporate developments (clinical progress and regained Nasdaq compliance) provide some offset, while valuation is limited by ongoing losses and no dividend.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics, with an emphasis on small-molecule drug candidates targeting highly resistant tumors. The company operates in the biopharmaceutical sector and taps public capital markets to fund its research and development pipeline and ongoing clinical programs.

Average Trading Volume: 331,613

Technical Sentiment Signal: Sell

Current Market Cap: $14.81M

Learn more about MBRX stock on TipRanks’ Stock Analysis page.